Breaks Categories: News

ThursdayAug 17, 2023 1:35 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Presentation of ‘Impressive’ Results from Proof-of-Concept Studies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in March of 2023 announced that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer, presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (“UCLA”). According to the announcement, the experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the company’s proprietary technology combining cell-, gene- and immunotherapy. The results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act. “I have…

Continue Reading

ThursdayAug 17, 2023 1:22 pm

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Spotlighted in New Cantor Fitzgerald Research Brief

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”) rating and 12-month price target of $6 for RVL Pharmaceutical shares, stating that RVLP’s commercial opportunities continue to be underappreciated and that upward earnings estimate revisions should drive the stock higher. The brief noted that…

Continue Reading

WednesdayAug 16, 2023 2:26 pm

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Enters into Agreements for $5M Registered Direct Offering

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has entered into definitive agreements. The offering is expected to close on or about Aug. 18, 2023, and will be subject to customary closing conditions. The company anticipates gross proceeds from the registered direct offering to total approximately $5 million; RVL Pharmaceuticals plans to use the funds for general corporate purposes. The registered direct offering agreements are for the purchase and sale of 11,870,846 of RVLP ordinary shares (or ordinary…

Continue Reading

WednesdayAug 16, 2023 12:35 pm

BioMedNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Subsidiary Announces Pricing of Its IPO

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that SRM Entertainment Inc. (NASDAQ: SRM), currently a subsidiary of the company, announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a price to the public of $5.00 per share. Gross proceeds from the offering are expected to be $6.25 million. The shares of SRM began began trading under the symbol SRM on the Nasdaq Capital Market on Aug. 15, 2023. Subject to the satisfaction of customary conditions, the offering is expected to close on Aug. 16, 2023. In…

Continue Reading

WednesdayAug 16, 2023 12:04 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies, called NanoAbs, targeting Interleukin-17 (“IL-17”), specifically for the treatment of psoriasis and psoriatic arthritis. The agreement is with the Max Planck Society and the University Medical Center Gottingen (“UMG”) and is part of…

Continue Reading

WednesdayAug 16, 2023 11:05 am

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the Fred Hutchinson Cancer Center were also, at that time, conducting studies of the company’s HIV platform with expected positive results. “We continue to prioritize the efficient research, development and commercialization of our promising oncology and HIV pipelines,” said the company’s CEO Dr. Mark Dybul. “Enochian’s…

Continue Reading

TuesdayAug 15, 2023 1:19 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in late 2022, was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors. “We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results,” said the company’s CEO Dr. Mark Dybul. “This technology could be transformative for oncology and for treating some of the world’s deadliest cancers, including pancreatic cancer, which has a five-year survival rate of just 5% to…

Continue Reading

TuesdayAug 15, 2023 12:38 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that its late breaking abstract about phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for Oct. 11-13, 2023. “We are excited about presenting our phase 1 first-in-human clinical data on Lucid-MS at this peer conference in Milan,” said Andrzej Chruscinski, M.D., Ph.D., VP, clinical and scientific affairs, Lucid Psycheceuticals. “Current…

Continue Reading

MondayAug 14, 2023 2:39 pm

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Q2 2023 Results, Strategic Business Review Update

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to extend runway, optimize marketing mix, and support business development efforts. While this streamlining had a modest unfavorable impact on sales during the quarter, we have gained greater conviction that driving consumer awareness is the next…

Continue Reading

MondayAug 14, 2023 2:01 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, is reporting on its financial and business results for the first quarter of the 2024 fiscal year, the period ended June 30, 2023. Highlights of the report include a 161% increase in net revenue, which totaled approximately $555,000 compared to $212,000 in the same quarter of 2023; continued momentum in the development of IGC’s phase 3 manufacturing facility located on the West Coast; a $12 million line…

Continue Reading